Friday, March 8, 2013
Baptist Medical Center is one of a select number of medical centers nationwide and the first in Mississippi offering Blue Light Cystoscopy with Cysview® (hexaminolevulinate HCl). Cysview is a newly approved optical imaging agent for the detection of papillary cancer of the bladder in patients with known or suspected bladder cancer.
Urologist Patrick Daily, MD, said, “This new procedure allows us to more accurately detect certain bladder tumors. The availability of Cysview signals the arrival of an innovative diagnostic technology for Mississippi residents who have or may have bladder cancer.”
Cysview is manufactured by Photocure, a Norwegian biotechnology company. Blue Light Cystoscopy with Cysview detects bladder cancer in individuals suspected or known to have lesion(s) in the bladder, based on a prior cystoscopy (examination of the bladder and urethra using a cystoscope, a thin, tube-like instrument with a light and a lens for viewing). It is used with the Karl Storz D-Light C Photodynamic Diagnostic (PDD) system, which includes a white light setting (Mode 1) to illuminate the bladder during a routine cystoscopy, and a blue light setting (Mode 2) to induce and view fluorescence, (i.e., Cysview) thereby enabling physicians to detect lesions in the bladder.
“Bladder cancer has a high recurrence rate. So, finding tumors at their earliest stage improves the chance to preserve the bladder and increases survival rate,” added Dr. Daily. “Blue Light Cystoscopy with Cysview represents an important advancement in diagnostic technology in over a century, enabling more accurate diagnosis of bladder tumors compared to the standard technique of white light cystoscopy alone. Patients with known or suspected bladder cancer can now come to Baptist to undergo diagnostic procedures administered by physicians who have been specially trained in the use of this innovative technology.”
More than 73,000 people in the US were diagnosed with cancer of the bladder in 2012, and an estimated 14,800 Americans died from the disease last year, according to the National Cancer Institute.1 Bladder cancer is the fourth most common type of cancer in men, and the eighth most common in women. Smoking is the most likely cause of bladder cancer.2 The most common initial sign of the disease is red-colored urine, which calls for urine cytology (tests performed on cells in urine to detect disease) and cystoscopy.3
The standard diagnostic procedure for bladder cancer combines urine cytology and white light cystoscopy.4 Although cytology provides specificity and sensitivity in detecting high-grade (highly abnormal) lesions, it provides no information on the location and extent of the disease. If the cells test positive for cancer, the next step is direct visual inspection of the urothelium and mucosa (the inside of the bladder) with white light cystoscopy to localize the tumors. The physician performs Transurethral resection (TUR), a form of cystoscopy-guided biopsy, of suspicious areas of the bladder, and then test the tissue samples to determine if they are malignant.5,6
Visist www.cysview.com for more information.
1 Bladder cancer. National Cancer Institute Web site.
http://www.cancer.gov/cancertopics/types/bladder. Accessed April 29, 2010.
2 What you need to know about bladder cancer. National Cancer Institute Web site.
httpt://www.cancer.gov/cancertopics/wyntk/bladder. Updated September 16, 2002. Accessed
April 30, 2010.
3 Bladder cancer treatment (PDQ®). National Cancer Institute Web site.
http://www.cancer.gov/cancertopics/pdq/treatment/bladder/Patient. Modified July 9, 2010.
Accessed July 20,
4 Goh AC, Lerner SP. Application of new technology in bladder cancer diagnosis and treatment.
World J Urol.
5 Klem B, Lappin G, Nicholson S, et al. Determination of the bioavailability of [14C]-
hexaminolevulinate using accelerator mass spectrometry after intravesical administration to
human volunteers. J Clin Pharmacol.
6 Frampton JE, Plosker GL. Hexyl aminolevulinate in the detection of bladder cancer. Drugs.
What can we help you find?close ×